Pharaoh accounts for 75% of Avalanche DEX volume. Of some $3.008B in DEX volume recorded by @Avax in the last 30 days, @PharaohExchange has driven an insane $2.242B, per DefiLlama data. This means that Pharaoh accounts for more than 74.5% of all $AVAX DEX volume, well ahead of @Uniswap $UNI in the #2# spot.

PHARITA’s 'DESERVE' VOCAL CLIP Show us your vocals Shorts ▶️ Reels ▶️ TikTok ▶️ #BABYMONSTER# #베이비몬스터# #PHARITA# #BABYMONSTER_DESERVE# #DESERVE_challenge#

PHARMACY CHAIN BIG CARING AIMS TO RAISE $500 MILLION TO $600 MILLION IN MALAYSIA IPO The company plans to launch the offering by the end of October and list on Bursa Malaysia by mid-November, according to sources, per Dow Jones

Pharrell Williams is seeking to have Chad Hugo's lawsuit against him dismissed, which his lawyers call “vague and ambiguous.” His lawyers say Hugo’s latest complaint names EARTHGANG’s “U Gotta” in its copyright ownership allegations but leaves out eight titles previously listed in that section. They argue he still hasn’t clearly explained his contributions or which copyrights he claims to own. Titles no longer listed in the complaint: ▫️ “Motomami” ▫️ “La Combi Versace” ▫️ “Cash In Cash Out” ▫️ “Love Is Not Written” ▫️ “Pure” ▫️ “Real One” ▫️ “Lost and Found” ▫️ “Freestyle” Pharrell's lawyers question why those details are still unclear after years of disputes and three versions of the complaint: “In fact, as incomprehensible as it is, it appears that Hugo has no idea which compositions or sound recordings he supposedly authored – even though he claims to have been there, right by [Pharrell's] side, the whole time.” If the copyright ownership and related accounting claims are thrown out, his lawyers also want the remaining state-law claims dismissed without prejudice. Those include breach of fiduciary duty, two accounting claims, and declaratory relief over LLC operating agreements. That would leave the door open for Hugo to pursue those state-law claims in state court.

Pharma firms closed biopharma buyouts worth over a hundred billion dollars in the first half of the year, racing to replace top selling medicines worth around $400 billion before patents expire. Leah Bennett of Concurrent explains

Pharma has the podium as Novo and Lilly stop talking about GLP-1 longevity and start measuring it, bringing early aging data to ARDD. #longevity# #GLP1# #aging# #geroscience# #ARDD#